Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Canada; University of Toronto, Toronto, ON, Canada..
Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
J Affect Disord. 2021 Jun 1;288:210-216. doi: 10.1016/j.jad.2021.03.053. Epub 2021 Mar 26.
Depression severity and efficacy measurement scales employed for rapid-acting treatments (e.g., ketamine) were initially validated in adults receiving conventional monoamine-based antidepressants. The emergence of rapid-acting antidepressants in psychiatry provides the impetus for outcome measures that have been validated as sensitive to change with rapid-acting treatments. Herein, we provide results validating the McIntyre and Rosenblat Rapid Response Scale (MARRRS).
Adults with treatment-resistant depression (TRD) receiving intravenous (IV) ketamine had depressive symptoms measured with the 16-Item Quick Inventory Depressive Symptoms Self-Report (QIDS-SR-16) and MARRRS at baseline and as a repeated measure across an acute course of four infusions. The MARRRS is a self-report measure assessing depressive symptoms during the past 72 hours.
Sixty-four patients (M = 45.4 ± 13.5) were included. The MARRRS had a high internal consistency across acute infusions as determined by Cronbach's alpha (0.84 to 0.94). There was significant convergent validity between the QIDS-SR-16 and MARRRS total scores across infusions (rs(292) = .87, p < .001); the MARRRS was also sensitive to change (rs(49) = .70, p < .001). Exploratory factor analysis revealed that MARRRS items loaded onto two factors (i.e., dysphoria and psychic anxiety) accounting for 63.4% of the total variance.
Heterogenous sample of adults with TRD receiving open-label treatment without placebo comparison.
The MARRRS is a brief validated self-report metric of depression symptom severity that is sensitive to change with the rapid-acting antidepressant ketamine. Measuring outcomes with the MARRRS informs treatment progress and facilitates treatment decisions in persons receiving the rapid-acting antidepressant ketamine. Studies of other rapid-acting antidepressants should incorporate outcome measures that are validated as sensitive to change with rapid-acting antidepressants.
用于快速作用治疗（例如，氯胺酮）的抑郁严重程度和疗效测量量表最初是在接受传统单胺类抗抑郁药的成年人中进行验证的。精神科快速作用抗抑郁药的出现为已被验证对快速作用治疗有反应的敏感的结果测量提供了动力。在此，我们提供了验证 McIntyre 和 Rosenblat 快速反应量表（MARRRS）的结果。
接受静脉（IV）氯胺酮治疗的治疗抵抗性抑郁症（TRD）成年人在基线和四次输注的急性过程中使用 16 项快速库存抑郁症状自我报告（QIDS-SR-16）和 MARRRS 测量抑郁症状。MARRRS 是一种自我报告措施，用于评估过去 72 小时内的抑郁症状。
共有 64 名患者（M=45.4±13.5）入选。MARRRS 在急性输注过程中具有较高的内部一致性，由 Cronbach 的 alpha 确定（0.84 至 0.94）。在输注过程中，QIDS-SR-16 和 MARRRS 总分之间存在显著的收敛效度（rs（292）=0.87，p<.001）；MARRRS 也对变化敏感（rs（49）=0.70，p<.001）。探索性因素分析表明，MARRRS 项目加载到两个因素上（即，抑郁和精神焦虑），占总方差的 63.4%。
接受开放标签治疗且无安慰剂对照的 TRD 成年患者异质样本。
MARRRS 是一种简短的验证性自我报告抑郁症状严重程度的度量标准，对快速作用抗抑郁药氯胺酮的变化敏感。使用 MARRRS 测量结果可提供治疗进展信息，并促进接受快速作用抗抑郁药氯胺酮治疗的人的治疗决策。其他快速作用抗抑郁药的研究应纳入已被验证对快速作用抗抑郁药有反应的敏感的结果测量。
